4.6 Review

Multifunctional and stimuli-responsive nanocarriers for targeted therapeutic delivery

期刊

EXPERT OPINION ON DRUG DELIVERY
卷 18, 期 2, 页码 205-227

出版社

TAYLOR & FRANCIS LTD
DOI: 10.1080/17425247.2021.1828339

关键词

Nanotherapeutics for cancer; nanoscale-based delivery systems; endogenous and exogenous stimuli-responsive nanocarriers; liposomes; targeted delivery

资金

  1. National Institutes of Health [R01 CA238871, R01 CA209818, R01 HL118312]

向作者/读者索取更多资源

Nanocarriers offer multiple benefits in targeted drug delivery, such as enhanced bioavailability and high drug loading capacity. Stimuli-responsive nanocarriers have the potential to provide controlled release of therapeutics in response to specific physiological conditions or external stimuli.
Introduction Nanocarrier-based delivery systems offer multiple benefits to overcome limitations of the traditional drug dosage forms, such as protection of the drug, enhanced bioavailability, targeted delivery to disease site, etc. Nanocarriers have exhibited tremendous successes in targeted delivery of therapeutics to the desired tissues and cells with improved bioavailability, high drug loading capacity, enhanced intracellular delivery, and better therapeutic effect. A specific design of stimuli-responsive nanocarriers allows for changing their structural and physicochemical properties in response to exogenous and endogenous stimuli. These nanocarriers show a promise in site specific controlled release of therapeutics under certain physiological conditions or external stimuli. Areas covered This review highlights recent progresses on the multifunctional and stimuli-sensitive nanocarriers for targeted therapeutic drug delivery applications. Expert opinion The progress from single functional to multifunctional nanocarriers has shown tremendous potential for targeted delivery of therapeutics. On our opinion, the future of targeted delivery of drugs, nucleic acids, and other substances belongs to the site-targeted multifunctional and stimuli-based nanoparticles with controlled release. Targeting of nanocarriers to the disease site enhance the efficacy of the treatment by delivering more therapeutics specifically to the affected cells and substantially limiting adverse side effects upon healthy organs, tissues, and cells.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据